PsychoactiveMap

NYU Langone Health psychedelic research trials

Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.

NYU Langone Health is listed with 6 registered studies counted here, in New York, United States. By compound: 6 psilocybin. By registry status: 4 recruiting and 2 not yet recruiting. By phase: 1 early phase 1, 1 phase 1 and 4 phase 2. Reported start years run from 2023 (earliest) to 2026 (latest).

Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.

Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.

At a glance

By compound

Compound hubStudies
Psilocybin6

By registry status

StatusStudiesShare
Recruiting467%
Not yet recruiting233%

By phase

PhaseStudiesShare
Early Phase 1117%
Phase 1117%
Phase 2467%

Registered studies

All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.

Title as registeredRegistry IDStatusPhaseRegistry datesCompound
Psilocybin as a Novel Therapy for Residual AnhedoniaNCT07607938RecruitingPhase 1Source start: 2026-09 (estimated)
Saved start 2026-07-01 differs from reported 2026-09; the saved day is not established by this observation.
Source date details

Start: 2026-09 (precision: month; source type: ESTIMATED; estimated)

Primary completion: 2030-08-01 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2030-09-30 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.566Z; registry revision: 2026-09-15 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterNCT07296328Not yet recruitingPhase 2Source start: 2026-01-15 (estimated)
Source date details

Start: 2026-01-15 (precision: day; source type: ESTIMATED; estimated)

Primary completion: 2027-04-01 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2027-04-01 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:18.483Z; registry revision: 2025-12-22 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Psilocybin for Opioid Use Disorder (OUD)NCT06796062RecruitingPhase 2Source start: 2025-12-17 (actual)
Source date details

Start: 2025-12-17 (precision: day; source type: ACTUAL; actual)

Primary completion: 2029-02 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2029-02 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-01-23 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUDNCT06349083RecruitingPhase 2Source start: 2026-09-01 (estimated)
Saved start 2025-08-26 differs from reported 2026-09-01; the saved day is not established by this observation.
Source date details

Start: 2026-09-01 (precision: day; source type: ESTIMATED; estimated)

Primary completion: 2030-05 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2030-05 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.349Z; registry revision: 2026-09-02 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)NCT06760533Not yet recruitingEarly Phase 1Source start: 2026-08 (estimated)
Saved start 2025-08-01 differs from reported 2026-08; the saved day is not established by this observation.
Source date details

Start: 2026-08 (precision: month; source type: ESTIMATED; estimated)

Primary completion: 2026-12 (precision: month; source type: ESTIMATED; estimated)

Study completion: 2026-12 (precision: month; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:17.780Z; registry revision: 2026-03-05 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin
Psilocybin Therapy in Advanced CancerNCT05398484RecruitingPhase 2Source start: 2023-05-24 (actual)
Source date details

Start: 2023-05-24 (precision: day; source type: ACTUAL; actual)

Primary completion: 2027-01-01 (precision: day; source type: ESTIMATED; estimated)

Study completion: 2027-01-01 (precision: day; source type: ESTIMATED; estimated)

Observation retrieved: 2026-10-31T20:06:16.239Z; registry revision: 2026-10-14 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred.

Psilocybin

About this data

Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.

Substance hubs for these compounds

Psilocybin

Country hub: United States

All trial hubs | Learn | Disclaimer